MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
MARAVAI LIFESCIENCES HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.99+0.20 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$3.69 (+111.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MARAVAI LIFESCIENCES HOLDINGS, INC. saw revenue fall 5.0% to $208.78M over the twelve months to Jun 30, 2026. Free cash flow was -$35.84M.
Revenue
$208.78M
-5.0% vs. a year earlier
Operating income
-$117.07M
TTM Q2 2026
Free cash flow
-$35.84M
TTM Q2 2026
EPS, diluted
-$0.53
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.03B
- P/E ratio
- –
- Price to sales
- 4.96
- Price to book
- 5.06
- Dividend yield
- –
- Free cash flow yield
- -3.46%
Fundamentals
- Revenue
- $208.78M
- Net income
- -$77.39M
- EPS, diluted
- -$0.53
- Free cash flow
- -$35.84M
- Book value per share
- $1.38
- Diluted shares
- 148M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$208.78M-5.0% YoY
Gross profit
$72.85M+8.5% YoY
Operating income
-$117.07M
Net income
-$77.39M
EPS, diluted
-$0.53
Free cash flow
-$35.84M
Reported periodTrailing twelve months